2nd Abu Dhabi Brain Conference 2022 Program Book

For adverse events and safety reporting, please send an email: PV-MEA@lilly.com For further information about Lilly and Lilly products, please contact us at the below address: UAE: Bldg. 25 - 6th Floor, Dubai Health Care City, Dubai, UAE, P.O. Box #25319, Tel.: (+971 4) 453 7800, Fax: (+971 4) 436 2399 © 2022 Eli Lilly and Company. All Rights Reserved. PP-GZ-AE-0443 References: 1. Emgality product information USPI. 2. Detke HC, Millen BA, Zhang Q, et al. Rapid onset of effect of galcanezumab for the prevention of episodic migraine: analysis of the EVOLVE studies. Headache. 2019;60(2):348-359. 3. Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75(9):1080–1088. 4. Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442-1454. 5. Stauffer VL, et al. Comparison between prefilled syringe and autoinjector devices on patient-reported experiences and pharmacokinetics in galcanezumab studies. Patient Prefer Adherence. 2018;12:1785-1795 Rapid onset from Day 1 and sustained through Month 6 1-4 CONSISTENT TO MAINTAIN Steady state after the first dose 1 120mg 1 × Month 1: Initial loading dose of two 120 mg injections From Month 2: One 120 mg injection per month LOADING DOSE Easy-to use, latex free pen 1,5 120mg 2 × No titration or dose increase needed 1 Scan the QR code for Abbreviated Prescribing Information As early as Day 1 (post injection), a significantly fewer percentage of patients treated with Emgality experienced a migraine headache day vs patients receiving placebo. (p=0.002 for EVOLVE-1 and p=0.038 for EVOLVE-2) 2*‡§ * Post-hoc analysis; ‡ Among those receiving Emgality, migraine headache day status on Day 1 (post injection) does not necessarily mean a particular patient will or will not respond in subsequent months; § Patients received a loading dose of 240 mg at the start of the first month.